Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1Lymphoid 1

Conditions

Mesothelioma, Malignant 1

Interventions

pembrolizumab 14Injections 13Pemetrexed 9Specimen Handling 8Carboplatin 8tislelizumab 7Interviews as Topic 7Cisplatin 7fludarabine 5atezolizumab 5Educational Status 5Cyclophosphamide 5Standard of Care 4Practice Guidelines as Topic 4Methods 4Fluorouracil 4Early Intervention, Educational 4Capecitabine 4Biopsy 4Bevacizumab 4Trastuzumab 3Platinum 3Paclitaxel 3Oxaliplatin 3Nivolumab 3Magnetic Resonance Spectroscopy 3Docetaxel 3Cetuximab 31,2-diaminocyclohexaneplatinum II citrate 3toripalimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Combined Modality Therapy × Other solid neoplasm × 30 days × Clear all
NCT06251310 2026-05-08

SW-682 in Advanced Solid Tumors

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 1 Recruiting
186 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡